万泽实业股份有限公司 关于参加 2025 年广东辖区投资者网上集体接待日活动的公告 | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 | | --- | | 虚假记载、误导性陈述或重大遗漏。 | 为进一步加强与投资者的互动交流，万泽实业股份有限公司（以下简 称"公司"）将参加由广东证监局、广东上市公司协会联合举办的"向新提 质 价值领航——2025 年广东辖区投资者集体接待日暨辖区上市公司中报 业绩说明会"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网 站（http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP， 参与本次互动交流，活动时间为 2025 年 9 月 19 日（周五）15:30-17:00。 证券代码：000534 证券简称：万泽股份 公告编号:2025-085 届时公司高管将在线就 2025 年半年度业绩、公司治理、发展战略、经 营状况、股权激励和可持续发展等投资者关心的问题，与投资者进行沟通 与交流，欢迎广大投资者踊跃参与！ 特此公告。 万泽实业股份有限公司 董 事 会 2025 年 9 月 16 日 ...

证券代码：000534 证券简称：万泽股份 公告编号:2025-084 2025 年 6 月 30 日，公司 2024 年度股东大会审议通过《关于拟向相关 金融机构申请综合授信额度的议案》《关于确定担保额度的议案》等议案， 同意公司（含公司合并报表范围内的下属子公司）向银行等金融机构申请 综合授信业务和与具有相应资质的金融公司合作进行融资业务，并由本公 司或子公司为上述融资业务提供连带责任担保，担保对象为公司及合并报 表范围内的下属子公司，担保方式包括但不限于保证担保、信用担保、资 产抵押、质押等以及因业务需要向相关方视情况提供的反担保，担保额度 不超过 56 亿元，担保额度的授权期限自公司 2024 年度股东大会审议通过 之日至公司 2025 年度股东大会召开之日止，担保额度在授权期限内可循环 使用，担保额度可根据实际情况在公司和下属子公司间进行调剂，其中万 泽航空的额度为 5 亿元，具体内容详见公司相关公告（公告编号：2025-024、 1 025、057）。因此本次公司为万泽航空所获授信额度提供的担保未超过上述 额度，无需提交公司董事会、股东大会审议批准。 上述担保提供前，本公司对万泽航空的担保余额为 ...

（文章来源：证券日报） 证券日报网讯 9月8日晚间，万泽股份发布公告称，公司2025年第三次临时股东大会于2025年9月8日召 开，审议通过了《关于回购注销公司部分限制性股票的议案》。 ...

证券代码：000534 证券简称：万泽股份 公告编号:2025-083 万泽实业股份有限公司 公司本次回购注销部分限制性股票将导致注册资本减少，根据《中华 人民共和国公司法》（以下简称"《公司法》"）等相关法律、法规的规定， 1 公司特此通知债权人。 二、通知债权人 公司本次回购注销部分限制性股票将导致公司股份总数减少 564,800 股，公司注册资本减少 564,800 元，在公司股份总数不发生其他变动的前提 下，公司股份总数将由 509,835,816 股减少至 509,271,016 股。根据《公司 法》等相关法律、法规的规定，债权人自本公告之日起 45 日内，有权凭有 效债权文件及相关凭证要求公司清偿债务或者提供相应担保。债权人未在 规定期限内行使上述权利的，不影响其债权的有效性，相关债务将由公司 根据原债权文件的约定继续履行。 关于回购注销部分限制性股票减少注册资本 暨通知债权人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 债权人可采用现场申报或信函的方式申报，债权申报所需材料：公司 债权人可持证明债权债务关系存在的合同、协议及其他凭证的原 ...

证券代码：000534 证券简称：万泽股份 公告编号: 2025-082 万泽实业股份有限公司 2025 年第三次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决提案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、会议召开时间 现场会议召开时间：2025年9月8日下午14时30分； 网络投票时间： 通过深圳证券交易所交易系统投票时间为：2025年9月8日9:15-9:25， 9:30-11:30，13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2025年9月8 日9:15-15:00。 2、会议召开地点 深圳市福田区福强路2016号云顶翠峰裙楼一楼会议室。 1 公司董事长黄振光先生。 6、会议的出席情况 参加现场会议和网络投票的股东（或股东代理人）合计185人，代表有 表决权的股份数为191,808,167股，占公司有表决权股份总数482,639,659股的 39.7415%（截至股权登记日公司总股本为509,835,816股，其 ...

广东信达律师事务所 股东大会法律意见书 中国 深圳 福田区益田路6001号太平金融大厦11、12楼 邮政编码：518038 11-12/F, Taiping Finance Tower, Yitian Road 6001, Futian District，Shenzhen, P. R. China 电话(Tel)：(0755)88265288 传真(Fax) ：(0755) 88265537 电子邮件（E-mail）：info@sundiallawfirm.com 网站（Website）：www. sundiallawfirm.com 广东信达律师事务所 关于万泽实业股份有限公司 2025 年第三次临时股东大会的法律意见书 信达会字[2025]第 250 号 致：万泽实业股份有限公司 广东信达律师事务所（下称"信达"）接受万泽实业股份有限公司（下称"贵 公司"或"公司"）的委托，指派信达律师出席贵公司 2025 年第三次临时股东大 会（下称"本次股东大会"），对贵公司本次股东大会的合法性进行见证，并出具 本《广东信达律师事务所关于万泽实业股份有限公司 2025 年第三次临时股东大 会的法律意见书》（下称"《股 ...

Core Viewpoint - The recent suspension of procurement qualifications for 28 commonly used clinical drugs in Shanghai due to non-compliance with price adjustment requirements reflects a broader national initiative aimed at regulating drug prices and ensuring fairness across provinces [2][3][9]. Group 1: Price Adjustment and Impact - The suspended drugs include essential items such as Banlangen Granules and Chuanxinlian Tablets, with notable companies like Taiji Group and Tianjin Tongrentang affected [2][3]. - The price adjustment initiative is part of a national strategy to eliminate price discrepancies between provinces, ensuring local prices do not exceed national monitoring levels [2][8]. - Previous price adjustments in Inner Mongolia for Banlangen Granules have set a precedent, indicating a coordinated effort across regions to enforce price compliance [7][9]. Group 2: Market Dynamics and Responses - The price adjustment has led to a complex dynamic where companies are reluctant to forfeit profit margins while also needing to comply with regulatory demands [7][9]. - Despite the procurement suspensions, there are no immediate concerns about clinical supply shortages, as there are numerous production batches available for the affected drugs [8]. - The price governance has expanded to include unselected drugs in national procurement, indicating a shift in regulatory focus [8][9]. Group 3: Regulatory Developments - The National Medical Insurance Administration has implemented various measures to monitor and control drug prices, including the use of big data and online price comparisons [10][9]. - The ongoing centralized procurement efforts have led to significant price reductions and increased competition among pharmaceutical companies [10][9]. - The regulatory landscape is evolving towards a more coordinated approach, although challenges remain in balancing regional cost variations and supply impacts [10].

Core Viewpoint - The company announced the completion of the second unlock period for its 2023 stock incentive plan, allowing for the release of restricted stocks [1] Summary by Relevant Sections - **Stock Incentive Plan** - The company has a stock incentive plan for 2023, which includes the first grant of restricted stocks [1] - **Unlock Conditions** - The conditions for the second unlock period have been met, allowing for the release of restricted stocks [1] - **Number of Participants and Shares** - A total of 168 participants are eligible for the release, with 1,665,000 shares being unlocked, representing 0.3266% of the company's total share capital [1] - **Listing Date** - The unlocked restricted stocks will be available for trading starting from September 5, 2025 [1]

Core Viewpoint - The company has announced the completion of the second unlock period for its 2023 equity incentive plan, allowing 1,665,000 restricted shares to be released for trading, which represents 0.3266% of the total share capital [1][9][17]. Summary by Sections Company Background - Wanze Industrial Co., Ltd. is implementing a 2023 equity incentive plan aimed at motivating employees through stock options [1]. Approval Process - The plan underwent several approval stages, including meetings of the board and supervisory committee, with independent opinions provided by independent directors [2][3][5][6]. Unlock Conditions - The second unlock period for the restricted shares has been achieved, with the conditions set forth in the incentive plan being met [9][10]. - The conditions for unlocking include no negative audit opinions, no inappropriate selections by regulatory bodies, and meeting specific performance targets [11][12]. Performance Metrics - The company must achieve either a revenue of 1,078.87 million yuan, representing a growth of 32.25% from 2022, or a net profit growth of 32.25% based on the previous year's figures to meet the performance criteria [12][13]. Shareholder Impact - The release of shares will affect the company's capital structure, reducing the proportion of restricted shares from 2.03% to 1.71% after the unlock [17]. Adjustments and Changes - The company has made adjustments to the repurchase price of the restricted shares, changing it from 8.58 yuan to 8.53 yuan per share [15][16]. - The total number of incentive recipients has been adjusted due to voluntary withdrawals and other factors, resulting in 168 eligible recipients for the second unlock period [15][16].

Group 1 - Mitsubishi Heavy Industries plans to double its gas turbine production capacity in the next two years due to a surge in global demand driven by increased electricity needs for AI data centers and renewable energy adjustments [1] - Siemens Energy reported a 20% year-on-year increase in new gas turbine orders, totaling €6.2 billion in Q2 2025, with a 144% growth in new equipment orders and a total backlog of €53 billion [1] - The demand for gas turbines is significantly influenced by the need for carbon dioxide reduction and energy transition, leading to a substantial increase in overseas orders [1] Group 2 - Yingliu Technology is identified as a leading domestic gas turbine blade manufacturer, currently holding a market share of only 1-2%, indicating significant growth potential [2] - Wanze shares focus on developing aerospace and naval power components, prioritizing urgent model products for research and production to ensure timely delivery [2]